BiomarkersHumans
Reference charts of plasma p‐tau217 as a pre‐screening tool in AD clinical trials
AAIC 2025 Abstract
Abstract
Background: Plasma phosphorylated tau (p‐tau) has been used as a pre‐screening tool in clinical trials. Using plasma p‐tau for pre‐screening may help identify individuals more likely to be Aβ‐PET positive, reducing the number of PET scans needed at enrollment and decreasing recruitment costs.
The paper
Pâmela C.L. Ferreira, Guilherme Povala, Bruna Bellaver, Tharick Ali Pascoal
Show 18 more authors
Guilherme Bauer‐Negrini, Cristiano Schaffer Aguzzoli, Firoza Zubeida Lussier, João Pedro Ferrari‐Souza, Douglas Teixeira Leffa, Marina Scop Madeiros, Carolina Soares, Helmet Talib Karim, Eduardo Rigon Zimmer, Chang Hyung Hong, Hyun Woong Roh, Ann D. Cohen, Pedro Rosa‐Neto, Dana Tudorascu, Beth Ellen Snitz, Thomas K. Karikari, Sterling C. Johnson, Sang Joon Son,University of Pittsburgh
AAIC 2025 Abstract · 26 Dec 2025 · CC BY
Presented at AAIC 2025
